

SUPPLEMENTARY MATERIALS FOR

Single nucleus transcriptomics of ventral midbrain identifies glial activation associated with chronic opioid use disorder

Julong Wei, Tova Y. Lambert, Aditi Valada, Nikhil Patel, Kellie Walker, Jayna Lenders, Carl J. Schmidt, Marina Iskhakova, Adnan Alazizi, Henriette Mair-Meijers, Deborah C. Mash, Francesca Luca, Roger Pique-Regi, Michael J Bannon, Schahram Akbarian

This supplementary file includes Figure S1- S10 and Table S1

Figure S1: Quality controls for VM single nuclei RNA-seq profiling.

Figure S2: Distribution of single nuclei with astrocyte, oligodendrocyte (ODC) and neuronal gene expression.

Figure S3: Cell type-specific expression of opioid receptor genes in the VM.

Figure S4: Differential gene expression across cohorts and cell types.

Figure S5: Opioid exposure affects the transcriptome of multiple subtypes of oligodendrocytes and microglia.

Figure S6: Cell-type specific pathway enrichments of differentially expressed genes in astrocytes and microglia.

Figure S7: Cell-type specific pathway enrichments of differentially expressed genes in oligodendrocytes (ODC) and non-dopaminergic neurons (non-DA).

Figure S8: Correlations between prior bulk RNA-seq study and the current RNA-seq analysis with single cell resolution.

Figure S9: Differentially expressed genes (DEGs) linked to Transcriptome Wide Association Studies (TWAS).

Figure S10: Tissue and demographic variables impacting single nuclei transcriptomes.

Table S1: Summary of Case and Control Cohort (Demographics and postmortem confounds)

Supplementary References

Figure S1




Figure S1: Quality controls for VM single nuclei RNA-seq profiling. (A) Dexamlet genotyping confirms 100% match by donor by pool against the background of all 95 donors. Y-axis represents the library pools for 95 individuals. X axis represents the individual, prefix of which denoting the expected library for each subject. Heat bar, percentage of nuclei for specific individual in the library, as indicated. (B-D) Violin plots, showing separately for 45 individuals who died by opioid overdose (blue) and 50 controls (red), (B) the distribution of numbers of nuclei per subject (1 sample = 1 subject), (C) the average number of genes per nucleus for each subject, and (D) the average numbers of reads per sample (1 sample = 1 subject). (E) UMAP plot for VM from 95 samples (present) study, (F, G) automatic annotation of major VM cell types from previous study in a smaller reference sample¹.

Figure S2








Figure S2: Distribution of single nuclei with astrocyte, oligodendrocyte (ODC) and neuronal gene expression. UMAP plots showing (A) separation of astrocyte and ODC nuclei, (B,C) expression of key (B) ODC marker genes, essentially limited to nuclei in ODC cluster, (C) astrocyte marker genes essentially limited to nuclei in the astrocyte cluster, (D,E) separation of neuronal nuclei into dopaminergic and non-dopaminergic subtypes which can be further split into subpopulations of nuclei expressing gabaergic (*GAD1*, *SLC32A1*) and glutamatergic (*SLC17A6*) neuron marker genes (see text).

Figure S3





Figure S3: Cell type-specific expression of opioid receptor genes in the VM. Violin plots depicting nuclear RNA levels for each of the 4 opioid receptor genes, *OPRM1*, *OPRK1*, *OPRD1* and *OPRL*, for each of the 10 major VM cell types (x-axes) as indicated (left) at the single nucleus level (Seurat, default parameters) and (right) as cell type by subject, data shown as at normalized CPM, log2 transformed (+1).

Figure S4



B











Figure S4: Differential gene expression across cohorts and cell types. (A) Z-score (disease control differential) correlations comparing (y-axis, Miami cohort; x-axis Detroit cohort) cohorts for 4 major glial populations, as indicated, and non-dopaminergic neurons in the VM. (B) Proportional representation of DEGs shared between specific pairs of glial subtypes, as indicated on x-axis, based on shared vs. opposite directionality.

Figure S5



A




B



C



D



#Nuclei of Opioid and Control for each subcluster

	Opioid	Control
Cluster 0	26414	39177
Cluster 1	21696	27453

Figure S5: Opioid exposure affects the transcriptome of multiple subtypes of oligodendrocytes and microglia. (A, B) UMAP subclusterings for (A) oligodendrocyte and microglial populations. (B) (left) Differential genes for ODC subclusters '0' and '1', as indicated, (right) Violin plots summarizing *OPALIN*, *S100B* and *RBFOX1* marker gene expression levels by subject (midbrain sample) and oligodendrocyte subtype, as indicated (C) Correlational matrix for differential gene expression (diseased versus control individuals) across all glial and neuronal populations, including subtypes (D) population structure of ODC single nuclei, diseased individuals vs. controls, as indicated.

Astrocyte ↑




GTPase
MAPK
activity
cascademesenchymal
by polymerase IIdefense
interferon-gamma
-mediated
interferon-gamma
virusameboidal-type
endothelial epithelium
migrationlocomotion component
motility movement

Figure S6


number of genes




p.adjust




Astrocyte ↓

embryonic
oligodendrocyte
morphogenesis
constituentcellular
response
cascade
stresslabyrinthine layer
blood vesselmyelination
peripheral
axon
ensheathmentestablishment
peroxisomal
targeting
peroxisome


number of genes




p.adjust




Microglia ↑

peptide antigen
MHC classcellular decreased
oxygen levelsresponse-activating
response-regulating
surface receptorneutrophil degranulation
immunity involvedprotein catabolic
targeting membrane


number of genes



p.adjust



Microglia ↓

N-acetylneuramate
metabolic process
activitydiet adipose
dietary tissueglial interleukin-1
migration productionleukocyte myeloid
activation differentiationnucleotide-binding
oligomerization domain
containing

number of genes



p.adjust





Figure S6: Cell-type specific pathway enrichments of differentially expressed genes in astrocytes and microglia. GO pathway enrichments for Biological Process, shown separately for up- and down-regulated DEGs, as indicated. See also Figure 3 and Data S5, including gene ratios (Data S5, column E).


ODC ↑




Non DA neuron ↑

- protein K48-linked deubiquitination
- histone H3-K9 modification


Figure S7



ODC ↓



Non DA neuron ↓



Count

● 2

p.adjust

0.045
0.050
0.055
0.060

Figure S7: Cell-type specific pathway enrichments of differentially expressed genes in oligodendrocytes (ODC) and non-dopaminergic neurons (Non-DA). GO pathway enrichments for Biological Process, shown separately for up- and down-regulated, as indicated. See also Figure 3 and Data S5, including gene ratios (Data S5, column E).




Figure S8





Figure S8: Correlations between prior bulk RNA-seq study and the current RNA-seq analysis with single cell resolution. Z-score (disease vs. control differential) correlations comparing (y-axis, bulk tissue RNA-seq study; x-axis, cell type specific RNA-seq at single nuclei resolution, current study) for 7 cell types, as indicated.

Figure S9

A



B






Figure S9: DEGs linked to TWAS. (A) Percentages representing, for each cell type the normalized proportion of DEGs overlapping with PhenomeXcan TWAS for substance use and medical or neurological traits, as indicated. We focused on Substantia Nigra (SN) gene expression and population-scale SUD phenotypes in PhenomeXcan. We included a total of 1,260 PhenomeXcan genes for a total of 40 SUD-related traits from the following categories of traits or diseases: alcohol, caffeine, marijuana, and smoking (*Data S6*). We also analyzed a recent study² that had called addiction risk genes via TWAS-guided integration of GTEx and PsychENCODE expression quantitative trait loci (see *Data S7,S8*). For GTEx, the study conducted TWAS analyses using MetaXcan via integration of eQTL from 13 brain regions and identified a total of 351 addiction risk factor genes (FDR<10%). For PsychENCODE, using the frontal and temporal cortex, TWAS analysis using S-PrediXcan identified a total of 410 addiction risk genes with FDR<10%². (B) Cell-type specific counts of genes called as DEG in current study *and* linked to substance use trait(s) in PhenomeXcan (see *Data S7*).

Figure S10

A



B



C




Figure S10: Tissue and demographic variables impacting single nuclei transcriptomes (A) Ventral midbrain region-of-interest. Drawing from representative coronally cut VM tissue block, showing the substantia nigra and adjacent portion of ventral tegmental area, the region-of-interest prepared by dissection and then further processed with the nuclei extraction protocol (see Methods). (B, C) Effects of tissue quality and demographic variables on single nuclei transcriptomes. (B) Frequency histogram, showing the fraction of mitochondrial genes/nucleus. Note fraction of <1% for the overwhelming majority, or 93.7% of nuclei. Note also that there are 1.8% of nuclei with >2% mitochondrial, 0.1% of nuclei with >10% mitochondrial and 0.025% of nuclei had >20% mitochondrial reads. (C) Linear regression testing for association of (left to right) nuclei number/donor, number of reads/nuclei, number of genes/nucleus and fraction of mitochondrial reads/nucleus with (top to bottom) donor age, brain tissue pH, postmortem interval (PMI), genotype principal component PC1 and PC2, and sex, *(**) P< 0.05, 0.01.

Table S1: Summary of Case and Control Cohort (Demographics and postmortem confounds)

Cohort	Category	N	Age (yrs)	Sex (M:F)	Race (W:AA:H)	PMI (hrs)	pH
Detroit	Opioid	22	43.86 ± 11.66	18:4	13:9:0	<20	6.46 ± 0.16
	Control	22	43.55 ± 9.39	18:4	13:9:0	<20	6.54 ± 0.20
Miami	Opioid	23	36.30 ± 9.04	20:3	18:3:2	20.91 ± 5.56	6.27 ± 0.14
	Control	28	37.21 ± 12.82	28:0	17:9:2	16.44 ± 5.04	6.34 ± 0.16

Supplemental References

1. Kamath T, *et al.* Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease. *Nat Neurosci* **25**, 588-595 (2022).
2. Hatoum AS, *et al.* Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders. *Nat Ment Health* **1**, 210-223 (2023).